Perspective Therapeutics’ (CATX) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Perspective Therapeutics (NYSEAMERICAN:CATX) in a research report released on Wednesday,Benzinga reports. Wedbush currently has a $11.00 price objective on the stock.

A number of other research analysts have also recently weighed in on CATX. BTIG Research reiterated a “buy” rating and set a $14.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday. Piper Sandler started coverage on shares of Perspective Therapeutics in a report on Thursday, February 19th. They issued an “overweight” rating and a $16.00 target price for the company. UBS Group reaffirmed a “buy” rating and set a $7.00 price target (down from $18.00) on shares of Perspective Therapeutics in a research note on Friday, November 21st. HC Wainwright upped their price target on shares of Perspective Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, January 30th. Finally, B. Riley Financial reduced their price objective on shares of Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. One analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. Based on data from MarketBeat, Perspective Therapeutics has a consensus rating of “Buy” and a consensus target price of $12.50.

Perspective Therapeutics Trading Down 3.3%

Shares of NYSEAMERICAN:CATX opened at $4.45 on Wednesday. Perspective Therapeutics has a 12 month low of $1.60 and a 12 month high of $6.16. The company has a quick ratio of 8.66, a current ratio of 5.17 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $4.37 and a 200 day moving average price of $3.44.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings data on Monday, March 16th. The company reported ($0.51) earnings per share for the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%.The company had revenue of $0.04 million for the quarter. As a group, research analysts expect that Perspective Therapeutics will post -0.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CATX. Aigen Investment Management LP purchased a new stake in shares of Perspective Therapeutics during the fourth quarter worth about $28,000. Russell Investments Group Ltd. lifted its stake in Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after buying an additional 5,475 shares in the last quarter. nVerses Capital LLC acquired a new stake in Perspective Therapeutics in the 4th quarter worth about $31,000. AXQ Capital LP boosted its holdings in Perspective Therapeutics by 24.2% in the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after buying an additional 2,481 shares during the last quarter. Finally, Engineers Gate Manager LP purchased a new stake in Perspective Therapeutics during the 4th quarter worth approximately $35,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Trending Headlines about Perspective Therapeutics

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: UBS raised its price target for CATX to $8.00, signaling increased upside from current levels and giving investors a higher valuation reference. UBS Group Raises Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $8.00
• Positive Sentiment: B. Riley Financial analyst says CATX stock price is expected to rise, which can attract momentum buying and support higher valuations. Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Expected to Rise, B. Riley Financial Analyst Says
• Positive Sentiment: Wedbush reaffirmed an “Outperform” rating on CATX, reinforcing buy-side sentiment from another boutique/specialist analyst. Wedbush Reaffirms “Outperform” Rating for Perspective Therapeutics (NYSEAMERICAN:CATX)
• Positive Sentiment: Brookline Capital Markets materially raised its FY2026 and quarter-by-quarter EPS estimates (still negative EPS, but less severe), suggesting improving expectations for the company’s financial trajectory. This reduces downside risk from prior forecasts. (Market data / analyst note)
• Positive Sentiment: BTIG initiated/maintained a Buy rating on CATX, adding further institutional buy-side support. Perspective Therapeutics (NYSEAMERICAN:CATX) Earns Buy Rating from BTIG Research
• Negative Sentiment: Royal Bank of Canada lowered expectations for CATX, which can add short-term pressure and offset some of the positive analyst actions. Royal Bank Of Canada Has Lowered Expectations for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.